ScoreWhy is Cisen Pharmaceutical Ltd. ?
1
Poor Management Efficiency with a low ROCE of 11.05%
- The company has been able to generate a Return on Capital Employed (avg) of 11.05% signifying low profitability per unit of total capital (equity and debt)
2
The company is Net-Debt Free
- Poor long term growth as Net Sales has grown by an annual rate of -1.89% and Operating profit at -5.50% over the last 5 years
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 7.85% signifying low profitability per unit of shareholders funds
3
Poor long term growth as Net Sales has grown by an annual rate of -1.89% and Operating profit at -5.50% over the last 5 years
4
Flat results in Jun 26
- NET PROFIT(9M) At CNY 265.01 MM has Grown at -20.38%
5
With ROE of 6.32%, it has a attractive valuation with a 0.89 Price to Book Value
- Over the past year, while the stock has generated a return of -30.78%, its profits have fallen by -16.6%
- At the current price, the company has a high dividend yield of 2.8
6
Underperformed the market in the last 1 year
- Even though the market (China Shanghai Composite) has generated returns of 3.40% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -30.78% returns
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Cisen Pharmaceutical Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Cisen Pharmaceutical Ltd. for you?
High Risk, Low Return
Absolute
Risk Adjusted
Volatility
Cisen Pharmaceutical Ltd.
-30.54%
-0.16
43.91%
China Shanghai Composite
3.23%
0.23
14.72%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
-1.89%
EBIT Growth (5y)
-5.50%
EBIT to Interest (avg)
94.29
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.39
Sales to Capital Employed (avg)
0.62
Tax Ratio
13.94%
Dividend Payout Ratio
37.40%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
10.17%
ROE (avg)
7.85%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
0.89
EV to EBIT
10.29
EV to EBITDA
6.41
EV to Capital Employed
0.79
EV to Sales
0.79
PEG Ratio
NA
Dividend Yield
2.78%
ROCE (Latest)
7.72%
ROE (Latest)
6.32%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Bearish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Mildly Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend3What is working for the Company
CASH AND EQV(HY)
Highest at CNY 7,234.87 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -57.32 %
INVENTORY TURNOVER RATIO(HY)
Highest at 2.6 times
-2What is not working for the Company
NET PROFIT(9M)
At CNY 265.01 MM has Grown at -20.38%
Here's what is working for Cisen Pharmaceutical Ltd.
Cash and Eqv
Highest at CNY 7,234.87 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debt-Equity Ratio
Lowest at -57.32 %
in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Inventory Turnover Ratio
Highest at 2.6 times
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its inventory faster
Inventory Turnover Ratio
Here's what is not working for Cisen Pharmaceutical Ltd.
Net Profit
At CNY 265.01 MM has Grown at -20.38%
Year on Year (YoY)MOJO Watch
Near term Net Profit trend is negative
Net Profit (CNY MM)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
